VDA-1102 led to an objective response rate of 56% in patients with mycosis fungoides, according to findings from an interim analysis of a phase 2a study.
Companies covered in this study are Medline Industries, Inc., Teleflex Incorporated, Boston Scientific Corporation, BD (Becton, Dickinson and Company),.
Mercury Bio Joins the Alliance for mRNA Medicines streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.